Henan Cancer Hospital
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT05911958
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05900089
- Locations
- π¨π³
Henan cancer hospital, Zhengzhou, Henan, China
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT05886140
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT05769010
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 85
- Registration Number
- NCT05747521
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT05718778
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05647330
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05640713
- Locations
- π¨π³
Henan cancer hospital, Zhengzhou, Henan, China
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05617859
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Application of Antiosteoporosis Therapy in Osteolysis
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05617846
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Β© Copyright 2024. All Rights Reserved by MedPath